Janak Patel
Family Medicine · Tampa, FLNPI 1932693421
Payments from drug & device makers
Across 61 payments — averaging $143.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$6K
- Sobi, Inc$2K
- Novo Nordisk$193
- Amgen$109
- Pfizer$97
- Lilly USA, LLC$89
- plus $618 from 15 others
What the payments were for
- Consulting fees$2,02523%
- Speaking & faculty fees$4,48451%
- Travel & lodging$1,02512%
- Food & beverage$1,23114%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 8 | $5,634 |
| Sobi, Inc | 1 | $2,025 |
| Novo Nordisk | 9 | $193 |
| Amgen | 6 | $109 |
| Pfizer | 4 | $97 |
| Lilly USA, LLC | 4 | $89 |
| AstraZeneca | 5 | $83 |
| Boehringer Ingelheim | 1 | $82 |
| Exact Sciences | 4 | $82 |
| Bayer | 4 | $62 |
| Sanofi Pasteur Inc. | 2 | $54 |
| GSK | 3 | $46 |
| AbbVie | 2 | $30 |
| Medtronic | 1 | $28 |
| Dynavax Technologies Corporation | 1 | $24 |
| Otsuka America Pharmaceutical, Inc. | 1 | $24 |
| Si-bone, Inc. | 1 | $23 |
| Astellas Pharma US Inc | 1 | $22 |
| Merck | 1 | $21 |
| Abbott | 1 | $21 |
| Lucid Diagnostics Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Synagis$2,025
How this compares
$8,765 in reported general payments places this provider in the 90th percentile of 7,282 family medicine providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 39 | $46,866 |
| OzempicSemaglutide | 42 | $42,786 |
| JardianceEmpagliflozin | 31 | $27,911 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 23 | $21,287 |
| LinzessLinaclotide | 11 | $5,988 |
| Atorvastatin Calcium | 262 | $2,416 |
| Gabapentin | 82 | $1,686 |
| Omeprazole | 74 | $1,329 |
| Wixela InhubFluticasone Propion/Salmeterol | 13 | $1,305 |
| Metoprolol Succinate | 106 | $1,228 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 47 | $1,187 |
| Lisinopril | 149 | $1,028 |
| Levothyroxine Sodium | 101 | $1,009 |
| Duloxetine Hcl | 45 | $870 |
| Tamsulosin Hcl | 55 | $857 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $97 | $46,86639 claims |
| Novo NordiskOzempic | $193 | $42,78642 claims |
| Boehringer IngelheimJardiance | $82 | $27,91131 claims |
| GSKTrelegy Ellipta | $46 | $21,28723 claims |
| AbbVieLinzess | $30 | $5,98811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,282 family medicine providers in Florida.
Other family medicine in Tampa
- Lon LynnTampa$9.7M
- Hugh ColemanDaytona Beach$115.5M
- Alexander WhiteDaytona Beach$69.7M
- Ronald SurowitzJupiter$38.3M
- Bruce RankinDeland$36.7M
- Keila HooverMiami$33.7M
- John NardandreaOcala$30.8M
- Jorge CasoMiami$22.6M
- Sharrell CooperPalm Coast$16.9M
- Christopher GallowayMelbourne$15.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.